General MedicationsORALGeneric

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

Standard Dose

1GM;EQ 50MG BASE

Max Dose

Refer to approved labeling

Primary Use

Marketing status: Discontinued

Summary

Approval overview SITAGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 204144 (ANDA).

Marketing status: Discontinued Active ingredient METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE Form and strength TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 50MG BASE Sponsor PH HEALTH Submission history Latest submission status date: 2025-06-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview SITAGLIPTIN AND METFORMIN HYDROCHLORIDE is listed in Drugs@FDA under application 204144 (ANDA). Marketing status: Discontinued Active ingredient METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE Form and strength TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 50MG BASE Sponsor PH HEALTH Submission history Latest submission status date: 2025-06-04 00:00:00. Submission type: ORIG.

Monitoring

• Review priority: STANDARD
• Marketing status: Discontinued

Interaction Notes

No interaction notes stored yet.